Asia Medical and General Atlantic Announce Strategic Partnership[:zh]亚洲医疗和泛大西洋投资集团宣布达成战略合作
September 17, 2018
Hong Kong Asia Medical Holding Limited (“Asia Medical”) today announced a strategic partnership with a $150 million investment from General Atlantic, a leading global growth equity firm. Asia Medical is a leading privately-owned Chinese healthcare services provider and hospital operator specializing in heart surgery and cardiology, which operates under the brand name ‘Asia Heart’. The strategic partnership marks the expansion of General Atlantic’s investment focus into the healthcare and biotechnology sector in China.
Founded in 1999 in Wuhan, Asia Medical currently operates two heart hospitals in Wuhan and Xinjiang, and co-manages four additional heart centers. The first Asia Heart hospital in Wuhan has become one of the top three heart hospitals in China based on volume of cardiovascular surgeries completed. This hospital not only serves patients from Hubei Province, but has also become the destination for heart-related diseases and surgeries for four neighboring provinces. In 2010, the company expanded its footprint with the acquisition of the Xinjiang hospital, which is now established as a top hospital in treating heart-related diseases in the province.
With a strong patient-centric philosophy and a top-notch medical and management team, Asia Medical’s continuous investment in clinical innovation, advanced data-driven, and digitalized medical process management allows the company to utilize modern treatment methods to address critical diseases. The hospitals under Asia Medical have also adopted an efficient dual-track management structure that separates clinical service from administrative work, which helps the company to drive excellence in hospital operation.
“We are proud that Asia Medical has established itself as a trusted medical services provider specializing in heart surgery and cardiology in China over the past 19 years,” said Mr. Tse Chun Ming, Founder and Chairman of Asia Medical. “We are excited to partner with General Atlantic and leverage the firm’s global healthcare expertise as we continue to provide high-quality healthcare services to a broad base of patients in China and beyond.”
According to data from China’s National Center for Cardiovascular Diseases, cardiovascular disease is the most prevalent chronic non-infectious disease in China and the leading cause of death. In a market dominated by public hospitals in China, Asia Medical has become one of the few private hospitals that has successfully established itself as a leading operator in the healthcare service space for cardiovascular.
“The healthcare industry in China has grown rapidly in recent years, with increased demand for healthcare services that specialize in the treatment of cardiovascular disease,” said Eric Zhang, Managing Director and Head of China at General Atlantic. “Asia Medical provides cutting-edge clinical solutions, combined with a highly dedicated founder and management team, and we are proud to partner with them as we expand our sector focus in China.”
This year, Asia Medical has opened a co-managed heart center in Hong Kong and completed an acquisition of a Japanese heart center. Its second hospital in Wuhan, Wuhan Asia General Hospital, will commence operation in November 2018. The hospital will operate several other departments including neurology and neurosurgery, pediatrics, obstetrics, and gynecology, which have strong synergies with its heart department to provide multi-specialty medical services. In its next phase of growth, Asia Medical plans to further develop its state-of-the-art hospital management systems and advanced medical technologies, including transcatheter aortic valve replacement. The company also intends to grow into a modern hospital group in cardiology space and expand internationally through organic growth and strategic acquisitions.
“With the increasing demand for high-end healthcare services in China, we are optimistic that medical groups with outstanding management will grow rapidly to meet the needs for consumption, technology, and service upgrade,” said Lefei Sun, Principal and Head of Healthcare for China at General Atlantic. “General Atlantic plans to continue to partner with visionary companies in the healthcare value chain in China and support them to grow into the leading companies in the industry.”
Drawing from 38 years of experience investing in over 300 global growth companies, General Atlantic partners with entrepreneurs and management teams who are building leading, high-growth businesses. The firm has USD $28 billion assets under management as of June 30, 2018 and focuses on investments across four sectors, including Consumer, Financial Services, Healthcare, and Technology, with support from the firm’s global team of experts. General Atlantic has deep expertise in the healthcare sector and is currently invested in leading companies, including Gingko Bioworks, KIMS Hospitals, and Landmark Health. The firm has been actively investing in China since 1999.
About Hong Kong Asia Medical Holding Limited
Hong Kong Asia Medical Holding Limited (“Asia Medical”), a leading privately-owned healthcare services provider and hospital operator specializing in heart surgery and cardiology, was founded in Wuhan, China, in 1999. Asia Medical’s mission is to grow Asia Heart, the brand name under which it operates, into a world-class healthcare services provider. Asia Medical currently has a network of two directly operated heart hospitals in Wuhan and Xinjiang and four co-managed heart centers in Mainland China and Hong Kong under the brand of “Asia Heart”, which provide a range of comprehensive medical services for the treatment of heart related diseases.
About General Atlantic
General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 115 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. www.generalatlantic.com.[:zh]香港亚洲医疗股份有限公司（“亚洲医疗”）今日宣布，与全球领先的投资机构美国泛大西洋投资集团（General Atlantic）达成战略合作，由泛大西洋投资集团向亚洲医疗投资1.5亿美元。亚洲医疗是行业领先的民营医疗服务供应商及心血管疾病专科医院运营商，旗下医院均以“亚心”品牌运营。此项战略合作的达成，也标志着泛大西洋投资集团的投资范围，进一步扩大到中国医疗和生命科技行业。
泛大西洋投资集团拥有38年的投资经验，至今已在全球范围内投资了300多家成长型企业，并与行业领先的高增长型企业的企业家和管理团队保持合作。截至2018年6月30日，该公司管理资产达280亿美元。在全球专家团队的支持下，公司专注于四个领域的投资，包括消费类、金融服务类、医疗健康类和科技类。泛大西洋投资集团在医疗领域拥有深厚的专业知识，并为行业领先的医疗和生命科技企业提供投资，包括Gingko Bioworks、KIMS Hospitals、Landmark Health等。自1999年以来，该公司一直致力拓展中国市场，在中国地区积极展开投资业务。
Edelman for General Atlantic[:zh]泛大西洋投资集团 爱德曼公关 [email protected] or [email protected][:zh][email protected] 或 [email protected]